April 22, 2024

Webinar: Advancing in vitro high-throughput transcriptomics for chemical toxicity testing

Webinar: Advancing in vitro high-throughput transcriptomics for chemical toxicity testing
About this webinar

Toxicity testing is on the cusp of transitioning away from expensive and ethically challenged animal-based methods, towards more efficient alternative approaches. Concurrently, advances in technologies that examine sub-lethal effects on gene expression have led to increased interest in the concept of transcriptomic points of departure (tPODs), or the threshold concentration beyond which a concerted response in gene expression may be expected, indicating the potential for adverse effects at the organismal level.

These concentrations have been found to be lower than (i.e. protective of) benchmark effect concentrations that can cause mortality and reproductive defects. Consequentially, there is growing scientific and regulatory interest in tPODs for applications in chemical screening and prioritization.

Hear from researchers from McGill University, as they present case studies in optimizing and advancing efficient workflows that couple in vitro exposures with ultraplexed library preparation using the QIAseq UPXome RNA Library Kit. This approach has increased the throughput of differential expression and dose-response analysis for tPODs derivation.

Additionally, learn how combining ultraplexed library preparation with mosquito® automated liquid handling has improved efficiency in two ways:

  • Shortening the overall library preparation protocol time
  • Reducing reagent usage by a half by miniaturizing protocol volumes
register now

Our latest News

discover more
RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]

Common cough syrup ingredient shows promise in treating serious lung disease

Common cough syrup ingredient shows promise in treating serious lung disease

EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions.  Scientists from EMBL Heidelberg were part of a […]

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp